SEP 28, 2021 9:00 AM PDT

The FDA approves drug to treat a bad cholesterol in children

WRITTEN BY: J. Bryce Ortiz

Familial hypercholesterolemia (FH) is a genetic disorder that afflicts approximately 1 in 250 people. Interestingly, while it is estimated that more than one million people in the United States have FH, less than 10% of these individual know they have it. FH is a disorder in which individuals have significantly high blood levels of low-density lipoprotein (LDL) cholesterol, more commonly known as “bad cholesterol.” When blood levels of this bad cholesterol become high, and remain high for extended periods of time, the cholesterol can accumulate into the walls of blood vessels which raises the chances of serious health problems such as heart attack or stroke. 

For most people, maintaining low levels of LDL cholesterol can be accomplished through lifestyle choices such as choosing a healthy diet, proper exercise, and quitting smoking. However, individuals who are affected by FH have high cholesterol levels early in life. This has many detrimental effects and in these individuals heart disease my start to develop earlier than the normal population, leading to heightened risks for heart attack and stroke at a young age. Because of this, early and frequent diagnostic testing has been encouraged for anyone with a family member with high cholesterol. 

Once an individual is diagnosed with FH, treatment can begin. These treatments include lifestyle changes or improvements in diet and exercise, and drug regimens. While there are many drugs to treat high cholesterol, many of the recently approved medications for FH were not approved for children of all ages. However, last week, the United States Food and Drug Administration (FDA) approved the drug Repatha (Manufactured by Amgen Inc.) for use in children as young as 10-years old. After the approval, David M. Reese, MD, vice president of research and development at Amgen said, “The approval of Repatha for pediatric patients with FH represents a much-needed adjunct treatment option for these children with genetically high cholesterol who are unable to manage their high LDL-C with other lipid-lowering agents alone.”

The FDA based their approval on recent clinical data in children aged 10-17 years old. The participants in the study had FH and received a single injection of Repatha monthly for 6 months. When the blood LDL levels of these patients were compared to patients who were not administered Repatha, the researchers found a 38% reduction in blood LDL levels. The approval of this lifesaving medication is a welcomed relief for pediatric FH patients, their families, and advocates. 

 

Sources: CDCMedlinePlusThe Cleveland ClinicThe FH foundationFDARepathaAmgen

About the Author
  • Science and medical writer | Researcher | Interested in the intersection between translational science, drug development, and policy
You May Also Like
SEP 22, 2021
Cancer
Whole Genome Sequencing for Cancer Diagnostics
SEP 22, 2021
Whole Genome Sequencing for Cancer Diagnostics
The human genome consists of genetic material known as DNA.  We all have unique DNA sequences made up of four bases ...
SEP 27, 2021
Health & Medicine
Gender-affirmation Surgery in Transgender Patients - Evidence for Regret?
SEP 27, 2021
Gender-affirmation Surgery in Transgender Patients - Evidence for Regret?
Gender-affirming care is a broad term used to describe medical, psychosocial, and surgical interventions delivered to tr ...
OCT 07, 2021
Drug Discovery & Development
Extended approval for a drug to treat children living with HIV
OCT 07, 2021
Extended approval for a drug to treat children living with HIV
On Monday October 4th, ViiV Healthcare announced that it had submitted an application to the United States Food and Drug ...
OCT 21, 2021
Coronavirus
FDA approves mixing and matching COVID booster shots
OCT 21, 2021
FDA approves mixing and matching COVID booster shots
On Wednesday, the United States Food and Drug Administration (FDA) approved Americans to be given a different ...
OCT 29, 2021
Drug Discovery & Development
A novel analogue of psilocin to treat mental health disorders
OCT 29, 2021
A novel analogue of psilocin to treat mental health disorders
Psilocybin and its metabolite psilocin are naturally occurring compounds that are commonly found in some genus of mushro ...
NOV 17, 2021
Drug Discovery & Development
FDA greenlights clinical trials for novel COVID-19 vaccine and delivery system
NOV 17, 2021
FDA greenlights clinical trials for novel COVID-19 vaccine and delivery system
Last week the United States Food and Drug Administration (FDA) authorized the biotechnology company Inovio to ...
Loading Comments...